Status:
COMPLETED
The Efect of Azithromicyn on Bronchopulmonary Displasia in Extremely Preterm and Very Preterm Infant
Lead Sponsor:
Indonesia University
Conditions:
Bronchopulmonary Dysplasia
Intraventricular Hemorrhage
Eligibility:
All Genders
25-32 years
Phase:
PHASE4
Brief Summary
This study was to see the effectiveness of azithromycin in preventing the incidence of bronchopulmonary dysphasia in extremely preterm and very premature infants. Inclusion criteria were infants with ...
Eligibility Criteria
Inclusion
- premature infant 25-31 weeks 6 days with respiratory distress,
Exclusion
- multiple congenital anomaly
Key Trial Info
Start Date :
June 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05311228
Start Date
June 8 2021
End Date
April 1 2022
Last Update
March 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Indonesia
Jakarta, DKI Jakarta, Indonesia